References
- Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol.17, 2762–2771 (1999).
- Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83, 588–593 (2000).
- Brada M, Hoang-Xuang K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12, 259–266 (2001).
- Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol.2, 552–560 (2001).
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
- Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol.10, 459–466 (2009).
- Wick W, Hartmann C, Engel C et al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol.27, 5874–5880 (2009).
- Hegi ME, Diserens AC, Gorlia T et al.MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352, 997–1003 (2005).
- Weller M, Stupp R, Reifenberger G et al.MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol.6, 39–51 (2010).
- Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
- Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27, 4733–4740 (2009).
- Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28, 2712–2718 (2010).
- Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28, 1168–1174 (2010).
- van den Bent M, Brandes A, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma. Report from EORTC Brain Tumor Group study 26034. J. Clin. Oncol.27, 1268–1274 (2009).
- Thiel E, Korfel A, Martus P et al. Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized Phase IV trial. J. Clin. Oncol.28(Suppl. 15) (2010) (Abstract 8008).
- Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med.361, 1173–1178 (2009).
Websites
- Radiation Therapy With or Without Temozolomide in Treating Patients With Anaplastic Glioma http://clinicaltrials.gov/ct2/show/NCT00626990
- A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma http://clinicaltrials.gov/ct2/show/NCT00943826
- Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma http://clinicaltrials.gov/ct2/show/NCT00884741
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status (CENTRIC) http://clinicaltrials.gov/ct2/show/NCT00689221